HCPCS code J1840 – Kanamycin sulfate injection

Key takeaways

HCPCS Code J1840 described injection, kanamycin sulfate, up to 500 mg, an aminoglycoside antibiotic given by intramuscular or intravenous injection.

CMS deleted J1840 with a termination date of March 31, 2024, so it is not payable for dates of service from April 1, 2024.

CMS named no replacement code, so kanamycin injection now goes on J3490 with the drug name, dose and NDC, once the payer’s policy confirms it.

Kanamycin injection supply in the US is very limited, so check availability and the payer’s coverage before you schedule the dose.

Billing the deleted code returns a denial for an invalid code, so update your charge master and any J1840 entries in your fee schedule.

HCPCS Code J1840: Definition and code status

HCPCS Code J1840 is the deleted Level II code for injection, kanamycin sulfate, up to 500 mg. CMS terminated it with effect from March 31, 2024.

A claim that carries J1840 for a date of service on or after April 1, 2024 is not payable. CMS assigned no replacement code, and J1850 (kanamycin, up to 75 mg) was terminated on the same date.

For kanamycin given now, most payers expect J3490, the unclassified drug code. That route needs more detail on the claim, so confirm the payer’s policy before the dose is given.

J1840 code details at a glance

The table below sets out the code’s official attributes and its status, so you can check a legacy claim or a charge master entry quickly.

What kanamycin sulfate injection is used for

Kanamycin sulfate is an aminoglycoside antibiotic for serious infections caused by susceptible gram-negative bacteria. These include certain strains of Escherichia coli, Klebsiella pneumoniae and Serratia marcescens.

It has also been used in regimens for drug-resistant tuberculosis. The World Health Organization no longer recommends kanamycin in those regimens and favors all-oral combinations instead.

Supply of kanamycin injection in the US is very limited. Before you plan a course, confirm that the pharmacy or wholesaler can source the product. Then record which product and NDC was given.

• Routes: IM injection or IV infusion
• Formulation: injectable solution (kanamycin sulfate injection)
• Non-injectable forms: other kanamycin forms fall outside this code and are rarely available in the US
• Inpatient stays: the drug is bundled into the DRG payment under the inpatient prospective payment system (IPPS), not billed separately

Is J1840 still valid? Code status and the 2024 deletion

No. J1840 was removed in the April 2024 quarterly HCPCS update, with a termination date of March 31, 2024. It stays valid only for dates of service up to that day.

The CGS Medicare April 2024 HCPCS update lists J1840 and J1850 as discontinued. No crosswalk to a new kanamycin code appears in the CMS update.

• Dates of service up to March 31, 2024: J1840 still applies, including on a corrected claim or an appeal.
• Dates of service from April 1, 2024: J1840 is invalid, and the claim line denies.
• Charge master and fee schedule: retire J1840 and J1850 so nobody picks them by habit.

The date of service decides which code the drug line carries, and each route needs different detail on the claim.

What to bill instead of J1840: J3490 and payer policy

With no replacement code, kanamycin injection now goes on J3490. That code covers drugs without a code of their own, and some payers publish their own instructions for it. Check the policy before you submit.

Unclassified drug lines draw more scrutiny in audits. A complete narrative and a matching NDC keep the line consistent with the record.

How to bill kanamycin injection under J3490

A clean claim for kanamycin given from April 1, 2024 needs five elements to line up with each other.

1. Enter J3490 on the drug line — never J1840 for these dates of service.
2. Describe the drug in the narrative — report the drug name, dose and route in item 19 of the CMS-1500. On the 837P, use the loop 2400 NTE segment.
3. Report the NDC — in the shaded area of item 24A, enter the N4 qualifier, the 11-digit NDC, the unit qualifier and the quantity. On the 837P, it goes in the LIN segment of loop 2410.
4. Set the units the payer expects — many payers want one unit on an unclassified line, with the dose in the narrative. Confirm this in the payer’s policy.
5. Link a specific diagnosis — use the confirmed infection or organism, not a symptom code.

Add the administration code on its own line, and record any prior authorization number the payer issued.

Pairing kanamycin with drug administration codes

The drug code covers the drug only. A separate CPT administration code describes how it was given. An IM dose usually goes on 96372, while an IV infusion starts with 96365.

Check the National Correct Coding Initiative (NCCI) edits before you submit. A pairing that the edits bundle returns a CO-97 denial.

Medicare coverage and payment for kanamycin

Medicare has no current J1840 payment rate, because the code is not payable for dates of service from April 1, 2024. A J1840 figure in an older pricing file does not apply to current claims.

Your Medicare Administrative Contractor (MAC) prices an unclassified drug line individually. Expect a request for the invoice or other pricing support. The CMS ASP pricing files still help you check rates for any other drug on the claim.

In hospital outpatient departments, unclassified drug lines are generally packaged into the related procedure payment rather than paid separately.

Prior authorization and coverage requirements

Traditional Medicare does not usually require prior authorization for an injectable antibiotic like kanamycin. Medicare Advantage plans and commercial payers often do, and policies vary by plan.

• Traditional Medicare: medical necessity rests on the clinical record, and your MAC’s local policies apply
• Medicare Advantage: check the plan’s prior authorization list before you give the dose
• Commercial payers: some ask for culture and susceptibility results as supporting documentation
• Medicaid: each state sets its own rules for physician-administered drugs, including NDC reporting

When a payer requires authorization, the record must show why kanamycin fits. That usually means a culture result naming a susceptible gram-negative organism. It also means a note on why other antibiotics were unsuitable, plus the prescribed dose.

ICD-10 diagnosis codes used with kanamycin injection

Link at least one ICD-10-CM code to the drug line to show medical necessity. The code should name a condition that kanamycin treats.

Payers often question drug lines that rest on a symptom code such as R50.9 or R05.9 (cough, unspecified). Code the confirmed organism or infection site instead.

If culture results are pending when the dose is given, document the suspected infection. Then update the diagnosis once the results arrive.

Common billing errors and claim denials

Most kanamycin denials now trace back to the code deletion or to a thin J3490 narrative. Understanding the denial codes payers use helps you fix each one on the first resubmission.

Effective denial management strategies for drug lines start before submission. Check the code’s status for the date of service, the narrative and the NDC every time.

Documentation requirements for kanamycin injection

A complete record protects the claim against medical necessity denials and pricing queries. Good medical billing compliance treats the clinical record as the first line of audit defense.

• Physician order — drug name (kanamycin sulfate), dose in mg, route and frequency
• Dose given — confirm it matches the order, or document the reason it differs
• Route — IM injection or IV infusion, stated in the encounter note
• Date and times — start and stop times support time-based infusion codes
• NDC and quantity — taken from the label of the vial used
• Medical necessity — culture and susceptibility results and the diagnosis
• Prior authorization number — where the payer requires one
• Invoice — kept on file for J3490 pricing requests

A structured superbill with fields for the NDC, dose and administration method keeps these details together for the biller.

How Pabau supports billing for unclassified drug claims

Today, the dose, the vial’s NDC and the invoice often sit in three different places. The biller then rebuilds the J3490 narrative from memory or from scanned paper.

Pabau’s practice software keeps the treatment note, digital forms and invoicing in the same patient record. The clinician records the drug, dose, route and NDC in the note. The biller reads the same record when building the claim.

Pabau’s claims software for practices works from that same record, so the narrative matches the chart. When a payer asks for supporting documents, they are already on file.

Keep drug claims and records together

Pabau keeps the treatment note, NDC details and invoice in one patient record, so your J3490 narratives match the chart.

Book a demo

Conclusion

Treat J1840 as a historical code. Use it only for dates of service up to March 31, 2024, and retire it from your charge master today.

For current kanamycin claims, the work moves to J3490. That means checking supply and payer policy first, then a narrative, NDC and diagnosis that agree with the chart.

The trade-off is slower, manual pricing, which a complete record makes predictable. Book a demo to see how Pabau keeps drug documentation and invoices in one patient record.

Continue your research

Need to understand how drug claim denials are categorized? Denial codes in medical billing explains the full CO/PR/OA reason code framework and how to match corrective actions to each code type.

Looking to streamline how your practice tracks claim submissions? Medical billing workflows explained walks through the end-to-end process from encounter to remittance.

Want a cleaner first-pass acceptance rate on drug claims? Clean claim submission covers the data elements payers validate automatically and how to prevent common formatting failures.

Billing another drug that has no code of its own? HCPCS code J3490 explains how the unclassified drug code works and what payers expect on the claim line.

Frequently asked questions